POLB Poolbeg Pharma Plc

TIDMPOLB

Poolbeg Pharma PLC

07 September 2021

RNS REACH

Poolbeg Pharma plc

POLB 001 US Patent update

7 September 2021 - Poolbeg Pharma (AIM: POLB), 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on the strengthening of its intellectual property (IP) position around lead product, POLB 001, a small molecule immunomodulator for the treatment of severe influenza.

As detailed in the Admission Document, Poolbeg has a worldwide license for POLB 001 and is developing a strong IP portfolio with patent protections in place covering the use of the class of p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment or prevention of severe influenza and hypercytokinaemia (or "cytokine storm"). The Company continues to also evaluate POLB 001's therapeutic uses beyond severe influenza.

The US Patent and Trademarks Office examiner reviewing the patent application around POLB 001 has indicated to the Company that the majority of the claims, including the main claim are allowable. The main claim relates to the use of p38 MAP kinase inhibitors as a class of compounds, including POLB 001, for the treatment of severe influenza through modulation of the immune response. Poolbeg anticipates receiving a formal patent grant in due course.

The European patent was granted prior to the IPO with claims to the treatment of severe influenza, which is characterised by symptoms that persist or recur for more than two days without signs of resolution, with a p38 MAP kinase inhibitor inhibiting the release of pro-inflammatory mediators from endothelial cells and pro-inflammatory cytokines from immune cells. This granted patent offers protection until 2037.

Assessment of the applications filed in other territories is ongoing.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma said:

"Our US patent assessment is going to plan and we look forward to updating our shareholders when we receive confirmation of its grant. With the fast-growing infectious disease market expected to exceed $250bn by 2025 and the current market for influenza already c. $800m, the protection of our intellectual property is very important. As stated in our AIM Admission Document upon listing, our intention is to continue to aggressively file patent applications to protect Poolbeg's assets."

- Ends -

Enquiries

 
  Poolbeg Pharma Plc 
   Jeremy Skillington, CEO 
   Ian O'Connell, CFO                         +353 (0) 1 644 0007 
  finnCap Ltd (Nominated Adviser & Joint 
   Broker) 
   Geoff Nash, James Thompson, Charlie 
   Beeson                                     +44 (0) 20 7220 0500 
  Arden Partners PLC (Joint Broker) 
   John Llewellyn-Lloyd, Louisa Waddell, 
   Oscair McGrath                             +44 (0) 207 614 5900 
  J&E Davy (Joint Broker) 
   Anthony Farrell, Niall Gilchrist           +353 (0) 1 679 6363 
  Instinctif Partners                         +44 (0) 20 7457 2020 
   Melanie Toyne Sewell, Rozi Morris, Tim      poolbeg@instinctif.com 
   Field 
 

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to licence or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. It already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further going forward and is in active discussions with AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.

For more information, please go to www.poolbegpharma.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRADKABNABKDFCK

(END) Dow Jones Newswires

September 07, 2021 02:00 ET (06:00 GMT)

Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024